Tvardi completes enrollment in Phase 2 IPF trial of TTI-101; topline data Q4 2025

Tvardi Therapeutics, Inc.

Completed enrollment in REVERT IPF Phase 2 trial of oral STAT3 inhibitor TTI-101 for idiopathic pulmonary fibrosis.
Trial is randomized, double-blind, placebo-controlled; endpoints include safety and lung function (FVC).
Topline data from the REVERT IPF trial is anticipated in the fourth quarter of 2025.
TTI-101 targets STAT3, a central mediator of fibrotic signaling pathways.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.